Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
An early look at data from the huge cancer conference boosts Allogene and Immunogen, while Arvinas and Cytomx suffer.
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.
A $4.9bn buyout of Forty Seven means that Gilead remains focused on oncology, though cell therapy bulls are none the wiser.